FREE CPD PROGRAM
The Neurologist's Guide to Modern MS Care
A comprehensive CPD collection summarising the 2024 McDonald Criteria updates, the application of high-efficacy treatments for MS, and an exclusive patient identification activity with optional nurse educator support.
A supported CPD program
In this collection
eLearning Module inc. categories 1, 2 + 3 components
3-Part Modern MS Module Set
About this education
With over 33,000 Australians now living with multiple sclerosis (MS) and prevalence on the rise,¹ the role of the Neurologist is more critical than ever. As this progressive condition places a significant burden on patients, best-practice guidelines have evolved to recommend the early use of high-efficacy therapies to improve long-term outcomes.² This shift in the treatment paradigm presents a crucial need for neurologists to enhance their knowledge to confidently identify and manage patients in this modern era of MS care.
This comprehensive CPD collection is designed to equip you with practical, up-to-date knowledge to optimise outcomes for your patients with MS. Delving into the entire MS management journey, this education covers the 2024 updates to the McDonald Diagnostic Criteria, the evidence supporting the paradigm shift to early high-efficacy therapy (HET), and a detailed review of the long-term safety and efficacy data for ofatumumab. You will gain the skills to formulate patient-centred management plans, confidently initiate HETs, and apply the latest clinical evidence in your neurology practice.
Furthermore, the Management of Multiple Sclerosis: Use of High-Efficacy Therapy in the Neurology Clinic module offers a unique opportunity to apply your learning through an optional supported patient identification activity, guided by a dedicated Wellness Clinical Services Nurse Educator.
The activities below can be completed separately or as a series at the discretion of the learner
ON-DEMAND eLEARNING MODULE
Consultant Neurologist | Director, Royal Melbourne Hospital Neuroimmunology Centre
Steering committee:
Description:
The McDonald Diagnostic Criteria for MS have been fundamentally revised in 2024. This module equips neurologists with the knowledge to apply the new criteria confidently. Participants will analyse key revisions, including the addition of new diagnostic tools such as Central Vein Signs (CVS), Paramagnetic Rim Lesions (PRLs), and Kappa free light chains (KFLCs). The module explores the unified diagnostic approach for both relapsing (RMS) and primary progressive (PPMS) forms of the disease.
By the end of this module, participants will be proficient in using the updated criteria to facilitate earlier and more accurate diagnoses, leading to better outcomes for MS patients.
Learning outcomes:
-
Critically analyse and compare the 2024 McDonald Diagnostic Criteria with the 2017 criteria to identify key revisions in diagnosing MS.
-
Explain and apply the new diagnostic tools and criteria.
-
Identify and apply the additional diagnostic considerations for specific patient populations, including children, individuals over 50, and those with comorbidities.
ON-DEMAND eLEARNING MODULE
Dr Michael Hayes
Consultant Neurologist
Dr Jessica Shipley
Consultant Neurologist
Steering committee:
Description:
This module, the second in a three part series, focuses on the evolving paradigm of MS management, with an emphasis on early, high-efficacy therapy. The content evaluates evidence for this approach and its application in clinical practice. It guides the formulation of patient-centred management plans, exploring factors like infection risk and comorbidities. Using case studies, it covers disease-modifying therapy (DMT) selection and how to tailor treatment to individual needs. The module also provides skills for identifying indicators for switching DMTs and how to prevent disease rebound, while integrating non-pharmacological interventions for a holistic approach.
Learning outcomes:
-
Evaluate the evidence for early high-efficacy therapy (HET) for multiple sclerosis (MS) and apply this paradigm shift to clinical practice.
-
Formulate a comprehensive patient-centred management plan that integrates disease-modifying therapy (DMT) selection with considerations such as infection risk and patient comorbidities.
-
Identify clinical and radiological indicators for switching DMTs and strategies to safely transition therapies.
-
Incorporate non-pharmacological interventions as part of a holistic approach to managing MS.
ON-DEMAND eLEARNING MODULE
Dr Nevin John
Neurologist & MS Specialist | Head of Multiple Sclerosis, Monash Health
Steering committee:
Description:
This module provides neurologists with a comprehensive overview of the long-term safety and efficacy data for ofatumumab, a HET used in Australia to treat relapsing multiple sclerosis (RMS). The module examines up to 7 years of data from the ASCLEPIOS I/II and ALITHIOS trials, focusing on key efficacy measures such as confirmed disability worsening and progression independent of relapse activity. It also addresses the long-term safety profile of ofatumumab, including its impact on immunoglobulin G (IgG) levels and infection risk. Finally, it highlights important considerations and clinical caveats for neurologists when interpreting long-term data.
Learning outcomes:
-
Evaluate the long-term (up to 7-year) efficacy and safety data for ofatumumab in patients with RMS.
-
Explain the clinical relevance of immunoglobulin G (IgG) levels and the reported trends in patients on long-term ofatumumab therapy.
-
Identify and address clinical caveats associated with interpreting the long-term follow-up data for ofatumumab.
How does supported CPD work?
Contemporary, flexible CPD for Neurologists
This CPD program combines the convenience of self-guided online learning (category 1 eLearning module + category 2 activity) with the option of a personalised, supported patient identification activity (category 3 activity), guided by a dedicated Nurse Educator from the Wellness Clinical Services Registered Nurse team.
NB: Clinicans are provided with the tools and information to independently complete the patient identification activity, without the direct support of a Nurse Educator. Get started here
LIVE WEBINAR w. Q&A
Multiple Sclerosis Webinar: Lorem ipsum dolor sit amet, consectetur
ID: XXXXXX
ID: XXXXXX
Ideal for:
-
General Practitioners
-
Practice Nurses
Wednesday 5 November 2025, 7:30-8:30pm AEDT
.webp)
Dr Kate Davey
General Practitioner
Prof Michaela Lucas
Immunologist
Dr Annika Smith
Dermatologist
Description:
CSU is a challenging condition that significantly impacts a patient's quality of life. As the first point of contact for these patients, GPs are in a unique position to improve outcomes through early diagnosis and appropriate management. This activity provides practical strategies to confidently differentiate CSU from other conditions. Participants will gain the skills to apply a structured approach to care, from assessing disease activity with validated tools to implementing the latest treatment guidelines. Ultimately, this course will empower GPs to optimise patient care and improve referral processes for complex cases.
Learning outcomes:
-
Recognise the key clinical features of Chronic Spontaneous Urticaria (CSU) and differentiate it from other urticarial conditions.
-
Utilise diagnostic and assessment tools to confirm a diagnosis and monitor CSU severity in primary care settings.
-
Implement effective first-line management strategies for CSU and identify appropriate referral pathways for patients requiring specialist care.
ON-DEMAND eLEARNING MODULE
Neurologist & MS Specialist | Head of Multiple Sclerosis, Monash Health
Steering committee:
Description:
This interactive module provides an essential update on the management of MS, reflecting the significant evolution in treatment over the last 20 years. With clinical guidelines now advocating for the early use of high-efficacy therapies (HETs), this course is designed to enhance your knowledge and improve your confidence in using HETs in the neurology clinic.
This module explores the latest clinical evidence on identifying patients likely to benefit from HETs, selecting the optimal therapy, and managing the key medical procedures required before and after initiating treatment. The module features interactive quizzes and practical patient case studies to help you apply your learning to real-world scenarios.
Learning outcomes:
-
Recognise the key characteristics of MS and its differential diagnoses.
-
Describe the range of interventions for managing MS and distinguish between high-efficacy therapies (HETs) and medium/low-efficacy treatments.
-
Describe the benefits of, and barriers to, the early initiation of HETs in newly diagnosed patients.
-
Appropriately initiate or transition patients to a HET, applying recommended monitoring and risk mitigation strategies.
Category 1, category 2 and category 3 CPD components available - see module for details
Interested in the supported patient identification activity?
Maximise the impact of your patient identification activity with the support of a highly experienced Nurse Educator from the Wellness Clinical Services team. Complete the form below and the team will be in touch to assess your eligibility for in-clinic or virtual support.
If you have questions regarding Praxhub's collection or use of your information, please visit our Terms of Use or contact privacy@praxhub.com
Praxhub acknowledges Novartis for its support of this education. The sponsor has provided no input into the content of this activity.
References:
-
Campbell JA, Simpson-Yap S, Taylor BV, et al. Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021. Mult Scler. Aug 2024;30(9):1113-1127. doi:10.1177/13524585241265890
-
Shipley J, Beharry J, Yeh W, et al. Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1. Med J Aust. Apr 21 2025;222(7):356-364. doi:10.5694/mja2.52578
Oct 2025 AU-29204